EPAS1 and acute myeloid leukemia: Subsequent genetic evidence, however, indicated that inactivation of Hif1a and/or Hif2a accelerates AML initiation, indicating a tumor-suppressor function for HIFs5,6, thus suggesting that one potential therapeutic strategy for AML is to pharmacologically enhance HIF stability.